ArticleDiscover oncology2025
Inflammation-driven prognostic model and immune landscape profiling in osteosarcoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic and Immunomodulatory Roles of BNIP3 in Osteosarcoma Revealed by Integrated Single-Cell and Bulk Transcriptomic Profiling.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma is the most common primary malignant bone tumor in adolescents and young adults, and its prognosis remains poor, particularly in metastatic cases. Chronic inflammation within the tumor microenvironment promotes disease progression and immune evasion, yet few prognostic models incorporate inflammation‑related molecular features.
methodsBulk RNA-seq data and clinical annotations of osteosarcoma patients were obtained from TCGA, and a curated inflammation gene set (top 500 genes by relevance) was defined. LASSO and Cox regression analyses identified prognostic genes, from which we built a risk‑scoring model; optimal cut‑offs were set by maximally selected rank statistics. Model performance was evaluated using Kaplan-Meier survival curves and time‑dependent ROC analysis. We then constructed and calibrated a nomogram combining key genes and metastasis status. Single‑cell RNA‑seq data (GSE1624554) were processed in Seurat to map inflammation gene expression across cell types. Immune infiltration differences between risk groups were assessed via ESTIMATE and ssGSEA. Differentially expressed genes underwent GO and KEGG enrichment analysis, and potential drug repurposing candidates were explored through cMap and molecular docking with Temozolomide.
resultsThe resulting 11‑gene signature stratified patients into high and low risk with markedly different overall survival (p < 0.001), achieving AUCs of 0.808, 0.883, and 0.879 at 1, 3, and 5 years, respectively. The nomogram demonstrated excellent calibration and discriminative ability. Single‑cell analysis revealed macrophage‑ and myeloid‑specific enrichment of CD163 and SAMHD1. Low‑risk tumors exhibited higher immune and stromal scores, increased CD8⁺ T‑cell and APC activity, and enrichment of cytokine‑related pathways. Pan‑cancer assessment highlighted context‑dependent roles for PPARG, TERT, and VEGFA. Molecular docking predicted a favorable binding energy (-6.8 kcal/mol) between TERT and Temozolomide.
conclusionsThis inflammation-related risk model provides a novel prognostic tool for osteosarcoma, elucidates the interplay between tumor inflammation and immune infiltration, and suggests potential therapeutic targets and drug repurposing strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.